RadNet (NASDAQ:RDNT) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Separately, Zacks Investment Research lowered shares of RadNet from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $15.50.

RadNet stock opened at $15.62 on Friday. The company has a debt-to-equity ratio of 4.49, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market cap of $726.69 million, a P/E ratio of 53.86, a PEG ratio of 5.38 and a beta of 0.27. RadNet has a 1-year low of $9.50 and a 1-year high of $16.54.

RadNet (NASDAQ:RDNT) last posted its earnings results on Thursday, August 9th. The medical research company reported $0.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02). The firm had revenue of $244.40 million for the quarter, compared to the consensus estimate of $239.34 million. RadNet had a positive return on equity of 17.00% and a negative net margin of 0.64%. The business’s revenue was up 6.3% on a year-over-year basis. During the same period last year, the company posted $0.11 EPS. Research analysts expect that RadNet will post 0.35 EPS for the current year.

In other news, insider Norman R. Hames sold 14,000 shares of the stock in a transaction on Thursday, September 20th. The shares were sold at an average price of $15.59, for a total value of $218,260.00. Following the transaction, the insider now owns 589,000 shares of the company’s stock, valued at approximately $9,182,510. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Norman R. Hames sold 10,000 shares of the stock in a transaction on Monday, August 20th. The stock was sold at an average price of $14.06, for a total transaction of $140,600.00. Following the completion of the transaction, the insider now directly owns 613,000 shares in the company, valued at approximately $8,618,780. The disclosure for this sale can be found here. Insiders sold a total of 34,000 shares of company stock worth $506,660 in the last three months. Insiders own 7.56% of the company’s stock.

Several large investors have recently modified their holdings of the company. Bessemer Group Inc. increased its holdings in shares of RadNet by 10.1% in the 2nd quarter. Bessemer Group Inc. now owns 43,500 shares of the medical research company’s stock worth $653,000 after buying an additional 4,000 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of RadNet by 0.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,550,709 shares of the medical research company’s stock worth $22,330,000 after buying an additional 4,117 shares during the last quarter. Cheyne Capital Management UK LLP increased its holdings in shares of RadNet by 1.5% in the 2nd quarter. Cheyne Capital Management UK LLP now owns 351,393 shares of the medical research company’s stock worth $5,271,000 after buying an additional 5,100 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of RadNet by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 39,205 shares of the medical research company’s stock worth $588,000 after buying an additional 5,398 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its holdings in shares of RadNet by 15.5% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 41,050 shares of the medical research company’s stock worth $616,000 after buying an additional 5,500 shares during the last quarter. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Featured Article: How to Use a Moving Average for TradingĀ 

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.